NCT02006290View on ClinicalTrials.gov

Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Parkinson's Disease
Interventions
DRUG

PF-06412562

single oral split dose 30+20 mg QD

DRUG

Placebo

tablet, matching placebo, QD

Trial Locations (5)

27612

Pfizer Investigational Site, Raleigh

33143

Pfizer Investigational Site, South Miami

33180

Pfizer Investigational Site, Aventura

33486

Pfizer Investigational Site, Baco Raton

48025

Pfizer Investigational Site, Bingham Farms

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02006290 - Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease | Biotech Hunter | Biotech Hunter